Vis enkel innførsel

dc.contributor.authorHoff, Mari
dc.contributor.authorSkovlund, Eva
dc.contributor.authorSkurtveit, Svetlana
dc.contributor.authorMeyer, Haakon E
dc.contributor.authorLanghammer, Arnulf
dc.contributor.authorSøgaard, Anne-Johanne
dc.contributor.authorSyversen, Unni
dc.contributor.authorForsmo, Siri
dc.contributor.authorAbrahamsen, Bo
dc.contributor.authorSchei, Berit
dc.date.accessioned2020-01-14T08:54:57Z
dc.date.available2020-01-14T08:54:57Z
dc.date.created2019-12-16T15:55:43Z
dc.date.issued2019
dc.identifier.citationOsteoporosis International. 2019, .nb_NO
dc.identifier.issn0937-941X
dc.identifier.urihttp://hdl.handle.net/11250/2636098
dc.description.abstractSummary Proton pump inhibitors (PPIs) have been linked to increased risk of fracture; the data have, however, been diverging. We did not find any increased risk of fractures among users of PPIs in a Norwegian population of 15,017 women and 13,241 men aged 50–85 years with detailed information about lifestyle and comorbidity. Introduction Proton pump inhibitors (PPIs) are widely prescribed and have been linked to increased risk of fracture. Methods We used data from the Nord-Trøndelag Health Study (HUNT3), The Fracture registry in Nord-Trøndelag, and the Norwegian Prescription Database, including 15,017 women and 13,241 men aged 50–85 years. The study population was followed from the date of participating in HUNT3 (2006–2008) until the date of first fracture (forearm or hip), death, or end of study (31 December 2012). The Cox proportional hazards model with time-dependent exposure to PPIs was applied, and each individual was considered as unexposed until the first prescriptions was filled. To be included, the prescription of PPIs should minimum be equivalent to 90 defined daily doses (DDD) in the period. Individuals were defined as exposed until 6 months after end of drug supply. Results The proportion of women and men using PPIs was 17.9% and 15.5%, respectively. During a median of 5.2 years follow-up, 266 women and 134 men had a first hip fracture and 662 women and 127 men, a first forearm fracture. The combined rate/1000 patient-years for forearm and hip fractures in women was 49.2 for users of PPIs compared with 64.1 among non-users; for men 18.6 and 19.8, respectively. The hazard ratios with 95% confidence interval for the first forearm or hip fracture among users of PPIs in the age-adjusted analysis were 0.82 (0.67–1.01) for women and 1.05 (0.72–1.52) for men. Adjusting for age, use of anti-osteoporotic drugs, and FRAX, the HR declined to 0.80 (0.65–0.98) in women and 1.00 (0.69–1.45) in men. Conclusions Use of PPIs was not associated with an increased risk of fractures.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Verlagnb_NO
dc.titleProton pump inhibitors and fracture risk. The HUNT study, Norway.nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber10nb_NO
dc.source.journalOsteoporosis Internationalnb_NO
dc.identifier.doi10.1007/s00198-019-05206-0
dc.identifier.cristin1761437
dc.description.localcodeThis is a post-peer-review, pre-copyedit version of an article. Locked until 18.11.2020 due to copyright restrictions. The final authenticated version is available online at: https://doi.org/10.1007/s00198-019-05206-0nb_NO
cristin.unitcode194,65,20,0
cristin.unitcode1920,9,0,0
cristin.unitcode194,65,15,0
cristin.unitcode1920,15,0,0
cristin.unitcode1920,13,0,0
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.unitnameKlinikk for ortopedi, revmatologi og hudsykdommer
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameMedisinsk klinikk
cristin.unitnameKvinneklinikken
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel